Condition: Marginal Zone Lymphoma · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Splenic Marginal Zone Lymphoma · Sponsor: Izidore Lossos, MD
The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
This description comes directly from the study's public registry record.
Izidore Lossos, MD · +1 (305) 2434787 · ilossos@med.miami.edu
Always discuss trial participation with your own doctor first.
| University of Miami | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06796998